» Articles » PMID: 26755942

Global and Regional Estimates of COPD Prevalence: Systematic Review and Meta-analysis

Overview
Journal J Glob Health
Date 2016 Jan 13
PMID 26755942
Citations 493
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The burden of chronic obstructive pulmonary disease (COPD) across many world regions is high. We aim to estimate COPD prevalence and number of disease cases for the years 1990 and 2010 across world regions based on the best available evidence in publicly accessible scientific databases.

Methods: We conducted a systematic search of Medline, EMBASE and Global Health for original, population-based studies providing spirometry-based prevalence rates of COPD across the world from January 1990 to December 2014. Random effects meta-analysis was conducted on extracted crude prevalence rates of COPD, with overall summaries of the meta-estimates (and confidence intervals) reported separately for World Health Organization (WHO) regions, the World Bank's income categories and settings (urban and rural). We developed a meta-regression epidemiological model that we used to estimate the prevalence of COPD in people aged 30 years or more.

Findings: Our search returned 37 472 publications. A total of 123 studies based on a spirometry-defined prevalence were retained for the review. From the meta-regression epidemiological model, we estimated about 227.3 million COPD cases in the year 1990 among people aged 30 years or more, corresponding to a global prevalence of 10.7% (95% confidence interval (CI) 7.3%-14.0%) in this age group. The number of COPD cases increased to 384 million in 2010, with a global prevalence of 11.7% (8.4%-15.0%). This increase of 68.9% was mainly driven by global demographic changes. Across WHO regions, the highest prevalence was estimated in the Americas (13.3% in 1990 and 15.2% in 2010), and the lowest in South East Asia (7.9% in 1990 and 9.7% in 2010). The percentage increase in COPD cases between 1990 and 2010 was the highest in the Eastern Mediterranean region (118.7%), followed by the African region (102.1%), while the European region recorded the lowest increase (22.5%). In 1990, we estimated about 120.9 million COPD cases among urban dwellers (prevalence of 13.2%) and 106.3 million cases among rural dwellers (prevalence of 8.8%). In 2010, there were more than 230 million COPD cases among urban dwellers (prevalence of 13.6%) and 153.7 million among rural dwellers (prevalence of 9.7%). The overall prevalence in men aged 30 years or more was 14.3% (95% CI 13.3%-15.3%) compared to 7.6% (95% CI 7.0%-8.2%) in women.

Conclusions: Our findings suggest a high and growing prevalence of COPD, both globally and regionally. There is a paucity of studies in Africa, South East Asia and the Eastern Mediterranean region. There is a need for governments, policy makers and international organizations to consider strengthening collaborations to address COPD globally.

Citing Articles

Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions.

Vu S, Veit K, Sadikot R Int J Mol Sci. 2025; 26(5).

PMID: 40076807 PMC: 11899978. DOI: 10.3390/ijms26052184.


A mixed-methods pilot study of domiciliary nasal high-flow therapy for breathlessness in people with chronic obstructive pulmonary disease who do not qualify for domiciliary long-term oxygen therapy.

Smallwood N, Pascoe A, Buchan C, Wong A, Currow D, Le B Ther Adv Respir Dis. 2025; 19:17534666251314722.

PMID: 40071312 PMC: 11898029. DOI: 10.1177/17534666251314722.


Comparative efficacy of traditional non-pharmacological add-on treatments in patients with stable chronic obstructive pulmonary disease: a systematic review and network meta-analysis.

Roh J, Leem J, Lee B, Kim K, Jung H Front Public Health. 2025; 13:1410342.

PMID: 40061465 PMC: 11885152. DOI: 10.3389/fpubh.2025.1410342.


Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients.

Greib A, Zhao S, Ploch M, Henricks J, Easterling R, Moodabagil M Oncoimmunology. 2025; 14(1):2469375.

PMID: 39981683 PMC: 11849934. DOI: 10.1080/2162402X.2025.2469375.


Heart Rate Variability and Peripheral Oxygen Saturation Levels in Chronic Obstructive Pulmonary Disease.

P A J, Mohideen B, Ashraf A, Thaha S, Abu Shajahan M, Nazar I Cureus. 2025; 17(1):e77401.

PMID: 39949428 PMC: 11822238. DOI: 10.7759/cureus.77401.


References
1.
Sichletidis L, Tsiotsios I, Gavriilidis A, Chloros D, Kottakis I, Daskalopoulou E . Prevalence of chronic obstructive pulmonary disease and rhinitis in northern Greece. Respiration. 2005; 72(3):270-7. DOI: 10.1159/000085368. View

2.
Jyrki-Tapani K, Sovijarvi A, Lundback B . Chronic obstructive pulmonary disease in Finland: prevalence and risk factors. COPD. 2006; 2(3):331-9. DOI: 10.1080/15412550500218122. View

3.
Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

4.
Parasuramalu B, Huliraj N, Prashanth Kumar S, Masthi N, Srinivasa Babu C . Prevalence of chronic obstructive pulmonary disease and its association with tobacco smoking and environmental tobacco smoke exposure among rural population. Indian J Public Health. 2014; 58(1):45-9. DOI: 10.4103/0019-557X.128166. View

5.
Deveci F, Deveci S, Turkoglu S, Turgut T, Kirkil G, Rahman S . The prevalence of chronic obstructive pulmonary disease in Elazig, Eastern Turkey. Eur J Intern Med. 2011; 22(2):172-6. DOI: 10.1016/j.ejim.2010.12.014. View